Sector revisions Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE 01:30:00 18/08/2026 am IST			5-day change	1st Jan Change
3.220 ^USD	+0.62%		+7.33%	+17.09%

14/08	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
11/08	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	Nbr of analysts
PERSPECTIVE THERAPEUTICS, INC.		14
LONZA GROUP AG		23
REVOLUTION MEDICINES, INC.		21
BEONE MEDICINES AG		27
IQVIA HOLDINGS INC.		18
CELLTRION, INC.		24
ASCENDIS PHARMA A/S	-	18
MEDPACE HOLDINGS, INC.		12
EUROFINS SCIENTIFIC SE		14
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.		14
ICON PUBLIC LIMITED COMPANY		16
PHARMARON BEIJING CO., LTD.		11
BIO-TECHNE CORPORATION		11
ABIVAX		6
PRAXIS PRECISION MEDICINES, INC.		19
APOGEE THERAPEUTICS, INC.		11
PROTAGONIST THERAPEUTICS, INC.		13
KYMERA THERAPEUTICS, INC.		22
IONIS PHARMACEUTICALS, INC.		21
TEMPUS AI, INC.		14
Average		16
Weighted average by Cap.		19